Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Transneuronix

Explore full profile

Transneuronix operates as a medical device company in the United States and Europe

Mount Arlington, United StatesFounded 1995Health Tech & Medtech
Valuation $250–500M Last recorded · 2005
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Transneuronix and the history behind them.

About Transneuronix

Transneuronix, Inc. operated as a medical device company with a specific focus on developing therapies for obesity. Founded in 1995 and based in Mount Arlington, New Jersey, the firm dedicated its research to the application of gastric electrical stimulation. The core of its business was the development of an implantable, pacemaker-like device intended to treat obesity by sending electrical pulses to the stomach. This device, known as the Transcend Implantable Gastric Stimulation (IGS) System, was designed to create a feeling of fullness, thereby reducing appetite and helping patients lose weight. The system included an implantable stimulator, a programming system, a software application card, and gastric stimulation leads.

The company's primary clients were obese individuals participating in clinical research studies. Transneuronix's business model revolved around the research, development, and eventual commercialization of this medical device. The company engaged in extensive clinical trials across the U.S. and Europe to validate the safety and efficacy of its gastric stimulation technology. A significant milestone for Transneuronix was the development of its Transcend system, which underwent multi-center studies to confirm its effectiveness in weight loss with minimal complications compared to control groups. The first gastric stimulator for treating morbid obesity based on this research was implanted in 1995.

On July 1, 2005, Transneuronix was acquired by Medtronic for approximately $260 million, a move that marked Medtronic's entry into the obesity treatment sector and led to the formation of its Medtronic Obesity Management business unit. The acquisition was considered a strategic failure for Medtronic in subsequent years. Following the acquisition, Medtronic continued the development of the technology, creating the Transcend II IPG. However, no gastric electrical stimulation (GES) devices have received FDA approval for the treatment of obesity in the United States, although the Transcend IGS was available in Europe for this purpose.

Source: Dealroom company data

At a glance

Status
Acquired
Founded
1995
Headquarters
Mount Arlington, United States
Open positions
None listed
Dealroom signal
20.0/100
Industry
Health
Sub-industry
Medical Devices
Sector
Health Tech & Medtech, Weight Management, Surgery, Metabolism, Hard Tech, DT and LS, science-based
Technology
Deep Tech
Client focus
b2b

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITION✓Exit Jun 2005 $269M $269M Medtronic —
SERIES B✓Equity / VC Dec 2004 $17M $67M Affinity Capital Management · Affinity Capital Management —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Transneuronix website traffic

Latest recorded traffic for Transneuronix is 0 monthly website visits.

Latest monthly visits0
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Affinity Capital Management

Other known investors1 additional known investor

  • Medtronic
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Mount Arlington HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Transneuronix on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Transneuronix’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.